Adjuvant Radiotherapy for Melanoma – The End of an Era? A Study of the Management of Resectable Melanoma Following Approval of Adjuvant Systemic Therapies

mycophenolate mofetil was given, however, the patient's condition continued to deteriorate and he died.Conclusions: Immune-checkpoint inhibitors are rarely associated with graft versus host desease.According to the literature, skin and mucosa symptoms appear after the first treatment, typically within 35 days.GVHD side effect are mostly associated with nivolumab (57,0%), pembrolizumab (24,7) and ipiplimumab (12,9%) monotherapies.The skin symptoms are typically severe and difficult to treat, in the case of GVHD occurring with immunotherapy, we can expect a mortality of 25.8%.